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Supramolecular aggregates as carriers 
of active principles
Supramolecular aggregates such as micelles and 
liposomes, obtained by aggregation of amphiphi-
lic compounds (Figure 1), have attracted great 
attention for their potential application as in vivo 
carriers of active principles. In the early 1970s, 
the use of liposomes as drug-carrier systems was 
proposed by Gregoriadis & Ryman [1]. They are 
considered nontoxic, biodegradable and non-
immunogenic. Owing to their size, which typi-
cally ranges in mean diameter from 50 to 300 nm 
for the systemically administered compounds, 
liposomes display some unique pharmacokinetic 
characteristics. These include clearance via the 
reticulo endothelial system (RES), which results 
in a relatively long systemic circulation time, and 
hepatic and splenic distribution. Furthermore, 
liposomes exhibit preferential extravasation and 
accumulation at the site of solid tumors due to 
increased endothelial permeability and reduced 
lymphatic drainage in these tissues, which has 
been defined as the enhanced permeability and 
retention effect [2]. On the other hand, the com-
position of the molecules used for the formation 
of the vesicular structure will, at least, affect the 
fate of liposomes from the site of their introduc-
tion as well as their interaction with components 
of the body (e.g., surface charge [3–6], serum 
proteins, lipoproteins, the opsonin system [7,8], 
the phagocytic system [9] and finally target 
cells [8,10,11]). The hydrophobic core of micelles 
and the inner cavity of liposomes are carrier com-
partments that accommodate a large amount of 
drugs or contrast agents, while the shell, consist-
ing of brush-like protecting corona, stabilizes 
the drugs in aqueous solution and reduces tox-
icity of the active principle in nontarget organs. 
Associating a drug with liposomes markedly 
changes its pharmacokinetic and pharmacody-
namic properties and lowers systemic toxicity; 
furthermore, the drug is prevented from early 
degradation and/or inactivation after introduc-
tion to the target organism [12–17]. In systemic 
administration of reporter compounds, micelles 
or liposomes should respect several base require-
ments: high loading capacity of a drug and/or 
contrast agent, biodegradability, long blood 
circulation times, slow plasma clearance and 
c ontrollable drug-release profiles. 
Examples of drugs in liposomal formulations 
are reported in Table 1. The most active drugs 
against breast cancer are currently the anthra-
cyclines and taxanes (paclitaxel and docetaxel). 
Many research efforts have been directed towards 
improving the safety profile of the anthracycline 
cytotoxics, doxorubicin (DOX) and daunoru-
bicin (DNR), along with vincristine, which are 
associated with severe cardio toxic side effects, 
although acute gastrointestinal effects and other 
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toxicities may also occur. For example, the alkyl-
ating agent DOX acts by intercalating into DNA 
and has been used in the liposomal formulation 
known as Doxil®. This liposomal DOX formu-
lation showed increased time in circulation and 
decreased cardiovascular-related toxicity when 
compared with free DOX [18]; whereas, encap-
sulated DOX liposomes combined with cyclo-
phosphamide, in an experimental pulmonary 
metastatic melanoma mouse model, showed 
high anti-tumor effect [19].
Strategies for the delivery of taxanes are under 
active investigation to increase tumor exposure 
and/or to reduce adverse effects such as neurotox-
icity, edema, asthenia and alopecia. In addition, 
special issues with the taxanes provide further 
rationale for the application of delivery s ystems. 
Both paclitaxel and docetaxel are poorly soluble 
in aqueous solutions, and have consequently 
been formulated with Cremaphor EL and 
polysorbate 80 (TWEEN 80), respectively. 
Unfortunately, these formulations are highly 
allergenic, require extensive premedication, and 
are responsible for most of the acute toxicities 
observed with taxane therapy, rather than the 
taxanes themselves. Consequently, alternative 
delivery strategies based on liposome-encapsu-
lated paclitaxel [20] and poly(l-glutamic acid)-
paclitaxel, a polymer conjugate [21], have been 
developed and tested in clinical trials. 
Other liposomal drugs in breast cancer 
include approved chemotherapic drugs such as 
vinca alkaloids, platinums and camptothecins. 
Moreover, development of alternative classes of 
potent anticancer agents based on liposome-
based systems for delivery of nucleic acids, such 
as antisense oligonucleotides and gene therapy 
constructs are currently under investigation.
A liposomal formulation of amphotericin B 
and AmBisome, is a potent antifungal drug 
currently used for the treatment of invasive 
aspergillosis. Upon administration, AmBisome 
remains intact in the blood and distributes 
to the tissues where fungal infections may 
occur [11]. Disruption of AmBisome is observed 
after attachment to the outside of fungal 
cells, resulting in fungal cell death. Although 
AmBisome exhibits less in vitro antifungal 
activity than amphotericin B in some cases 
[11,22–24], much higher doses of AmBisome can 
be administered safely, resulting in an improved 
therapeutic p rofile [25].
Moreover, Mayer et al. have investigated the 
application of liposomes as a delivery vehicle 
for drug combinations [26]. The use of drug 
combin ations is a widely adopted strategy in 
clinical cancer therapy. Combinations of iri-
notecan/fluoxuridine, DNR/cytarabine, cispla-
tin/DNR and DOX/verapamil was shown to be 
highly effective against cells that are multidrug 
r esistant [27]. 
Several supramolecular aggregates have also 
been developed as carriers of contrast agents in 
MRI. They are based on multimeric or mac-
romolecular contrast agents in which a large 
n umber of paramagnetic gadolinium (Gd) 
complexes are combined together and the total 
relaxivity, that is the critical parameter to have 
contrast in MRI images, results from the single 
contrib ution of each Gd ion [28,29]. In particular, 
three classes of nonspecific contrast agents have 
been developed:
n	Aggregates obtained directly by the self- 
assembly of amphiphilic chelating agents;
n	Mixed aggregates containing synthetic 
amphiphilic chelating agents and one or more 
commercial phospholipids;
n	Self-assembling aggregates of polymeric 
amphiphiles that incorporate contrast agents. 
Micelles and liposomes are taken up to a large 
extent by the RES. This property makes supra-
molecular aggregates excellent candidates as 
possible carriers of Gd(III)-chelates to enhance 
the contrast efficacy and to change the phar-
macokinetic properties of MRI contrast agents. 
The first studies on the use of liposomes as car-
riers of MRI contrast agents appeared in the 
literature in the 1980s [30–32]. There have been 
two main approaches in the development of 
liposomal contrast agents: in the first one, con-
trast agents are entrapped within the internal 
Figure 1. Supramolecular aggregates (micelles and liposomes) obtained 
by assembling amphiphilic molecules consisting of a hydrophobic and a 
hydrophilic moiety in aqueous solution. 
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aqueous space of liposomes [30]; in the second 
approach, lipophilic contrast agents are incor-
porated in the lipid bilayer of the liposom [31,32]. 
Classical Gd complexes such as Gd–diethylene-
triamine penta-acetic acid (DTPA), Gd–DTPA-
bis(methoxyethylamide), and Gd–HPDO3A 
have been loaded within the internal aqueous 
space of lipid vesicles: the main target for such 
supramolecular aggregates is the liver, given the 
avid accumulation of these aggregates by Kupffer 
cells, and the relatively slow clearance of the 
Gd complexes once internalized [33]. While 
Table 1. Examples of drugs in liposomal formulations.
Drug Application Commercial name Composition of liposomes
Amikacin Bacterial infections MiKasome™ HSPC/CH/DSPG
Adriamycin (DOX) Stomach cancer – DPPC/CH
Ampicilin Listeria monocytogenes – CH:PC:PS (5:4:1)
CH:DSPC:DPPG (10:10:1)
Annamycin Kaposi’s sarcoma
breast cancer, leukemia
Annamycin DMPC:DMPG (7:3)
Amphotericin B[11,22–25] Systemic fungal infections AmBisome® HSPC/CH/DSPG
All–trans-retinoic acid Acute promyelocytic leukemia,
lymphoma, prostate cancer
ATRAGEN® DMPC/soybean oil
Muramyl dipeptide Immunostimulator – DSPC:PS (1:1)
1-b-d-arabinofuranozidecytozine Leukemia – SM/PC:CH (1:1:1)
Ciprofloxacine Pseudomonas aeruginosa – DPPC
Clodronate Macrophage suppression – PC/CH
Cis-diaminodichloro-platinum(II) Cancers – PS/PC
Cyclosporin Immunosuppressor – PC/CH
Chloroquine Malaria – PC:PG:CH (10:1:5)
Cu/Zn superoxide dismutase Anti-inflammatory – DPPC:CH:stearylamine (7:2:1)
DOX [18] Cancers Myocet® PC:CH (5:5)
DOX [19] Cancers Doxil HSPC/CH/PEG–DSPE
DOX Breast cancer EVACET™ eggPC:chol (55:45)
Daunorubicin Cancers DaunoXome® DSPC/CH
Ganciclovir Cytomegalovirus retinitis – PC/CH:sodium deoxycholate (12:1.7:1)
IL-2 Immunostimulant – DMPC
Leukotriene A4 Not estimated – PC:DCP:CH (7:2:1)
Lipid A Immunoadjuvant – DMPC:DMPG/CH (0.9:0.1:0.75)
Mitoxantron Colon cancer – PC:CH (7:1)
Methotrexate Cancers – DPPC:PI (18:2 w/w)
Nystatin Systemic fungal infections NYOTRAN™ DMPC: DMPG (7:3)
Na3(B20H17NH3) Cancers – DSPC/CH
Platinum drugs (e.g., cisplatin) Mezotelioma PLATAR bis-NDDP
Lurtotecan Cancers NX 211 HSPC:CH (2:1)
Oligonucleotides against c–myc Cancers INXC–6295 DSPC/CH/DODAP/PEGCerC14 (25:45:20:10)
Prostaglandin E1 Anti-inflammatory – PC
Ribavirin Herpes simplex – DPPC:CH:DCP (2.0:1.5:0.22)
Streptosotocin Lymphocyte activator – DMPC:CH (2:1)
Suramin Trypanosomes – DPPC
Muramyl tripeptide Immunostimulant – PC:PS (7:3)
Vincristin Cancers VincaXome DSPC/CH
Vincristin Cancers, lymphoma Onco TCS DSPC/CH
Various drugs and contrasts Diagnostics of various diseases LipoMASC™ PEG–liposomes
CH: Cholesterol; DCP: Dicetylphosphate; DMPC: Dimyristoylphosphatidylcholine; DMPG: Dimyristoyl phosphatidylglycerol; DODAP: 1,2-dioleoyl-3-dimethyl-
ammonium propane; DPPC: Dipalmitoylphosphatidylcholine; DPPG: Dipalmitoylphosphatidylglycerol; DSPC: Distearoylphosphatidylcholine;  
DSPG: Distearoylphosphatidylglycerol; DOX: Doxorubicin; HSPC: Hydrogenated soya phosphatidylcholine (hydrogenated soya lecithin); NDDP: Neodecanoate 
diaminocyclohexane platinum; PC: Phosphatidylcholine; PegCerC14: 1-O-(2’-(w-methoxy-polyethyleneglycol) succinoyl)-2-N-myristoylsphingosine; 
PEG–DSPE: Polyethylene glycol-phosphatidylethanolamine derivative; PEG-liposomes: Liposomes modified with components containing a polyethylene glycol;  
PG: Phosphatidylglycerol; PI: Phosphatidylinositol; PS: Phosphatidylserine; SM: Sphingomyelin.
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studying blood concentrations of these aggre-
gates to evaluate the possibility of using these 
liposomes for MRI application, it was observed 
that the enhancement of relaxivity is limited, 
as it is approximately two- to five-times lower 
compared with the same concentrations of free 
Gd complexes in solution. The relaxivity of the 
entrapped paramagnetic species appears to be 
lowered because of the limited exchange of bulk 
water with the contrast agents [30,34] under these 
conditions. This slow exchange is caused by the 
low permeability of the liposomal membrane to 
water [35]. Thus the second approach, where a 
hydrophilic chelating agent is covalently linked 
to a hydrophobic chain, may be more effective. 
In this scheme, the lipid part of the molecule 
is anchored in the liposome bilayer while the 
more hydrophilic Gd complex is localized on 
the liposome surface [36,37]. Several chelat-
ing probes of this type have been developed 
for liposome membrane incorporation. This 
approach results in an improved ionic relaxiv-
ity of the metal compared with the approach 
of encapsulating the paramagnetic molecules 
in the aqueous inter ior liposomal space, and 
compared with low molecular weight (MW) 
complexes [38]. None of the studied liposomal 
aggregates derivatized with paramagnetic Gd 
complexes have reached the market. 
Target-selective  
supramolecular aggregates
Labeling of supramolecular aggregates with 
bioactive markers able to direct them toward 
specific biological target receptors has led to 
next generation delivery systems for active prin-
ciples [39]. The bioactive markers commonly used 
to prepare target-selective supramolecular aggre-
gates are peptides and antibodies [40–42]. Entire 
antibodies, or their fragments also present the 
advantage of maintaining their in vivo stability 
and binding properties when coupled to supra-
molecular aggregates. However, their high MW 
could prevent bioavailability and circulation 
properties of the full aggregate; on the contrary 
low MW peptides, if they remain stable in vivo, 
well exposed on the aggregate surface, and in 
appropriate conformation for binding to a tar-
get receptor, could be more promising tools for 
selective delivery of supramolecular a ggregates 
to the cellular target.
Different synthetic procedures have been 
developed to introduce bioactive molecules 
to the external surface of the supramolecular 
aggregate [43]. The choice of synthetic strategy 
depends on whether coupling is performed 
before or after assembly of the supramolecular 
aggregate. The obvious goal of each approach 
is to achieve high coupling efficiency, but with 
the ligand retaining full binding affinity for its 
target receptor. The coupling of a ligand after 
the aggregate has been assembled involves the 
introduction of suitable activated functional 
groups onto the terminus of one of the aggregate 
components. Activated functional groups must 
be compatible with the aggregation process and 
should remain available on the aggregate surface 
for efficient chemical ligation of the bioactive 
ligand. As schematized in Figure 2, route 1, an 
example of this approach consists in the prepa-
ration of liposomes or micelles containing a 
1,2-distearoyl-sn-glycero-3-phosphoethanol-
amine-N-(maleimide) (DSPE)-polyethylene 
glycol (PEG) monomer derivatized with a 
N-maleimido function on the distal end of the 
DSPE–PEG monomer; after aggregate forma-
tion the externally exposed N-maleimido func-
tion reacts with the bioactive molecule, accord-
ing to the sulphydryl–maleimide coupling 
method, to give the labeled supramolecular 
aggregate. Another example of this approach is 
based on the obtainment of biotinylated aggre-
gates using a biotinylated liphophilic monomer 
in the surfactant mixture; in a two-step process 
the biotinylated supramolecular aggregates react 
with avidin and then with the biotinylated pep-
tide or antibody giving a noncovalently labeled 
compound (Figure 2, route 2). This strategy 
has proven to be particularly successful for the 
coupling of large ligands such as monoclonal 
antibodies. The coupling of a bioactive ligand 
to an aggregate component before aggregation 
is, in principle, chemically less complicated, 
but has the disadvantage that, at least in the 
case of liposomes, following final assembly of 
the aggregate a fraction of the conjugated bio-
active ligand remains entrapped in the interior 
region and is not more available for receptor 
binding. This labeling procedure, based on 
the use of amphiphilic peptides that assemble 
together with other amphiphilic monomers in 
the peptide-labeled supramolecular aggregates, 
is schematized in Figure 2, route 3.
These procedures have been successfully devel-
oped to prepare target-selective supra molecular 
aggregates, labeled with bioactive markers and 
loaded with active drugs acting as target-selective 
drug carriers [42,44], or, if labeled with a pool of Gd 
complexes, acting as target-selective MRI contrast 
agents [45–47].
Route 1 Route 2 Route 3
A
A
A
A
2)1)
Avidin Biotin–mAb
xxxxx–mAbxxxxx–peptide
Biotin–peptidePeptide amphiphilic monomerDSPE-PEG-N-maleimido
Biotinylated amphiphilic 
monomer
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For example, PEGylated paramagnetic lipo-
somes (immuno-liposomes) derivatized with anti-
body molecules that are coupled to the distal end 
of PEG chains have been developed [48]. The cho-
sen antibody is able to detect E-selectin expression 
on human umbilical vein endothelial cells, this 
is an attractive model for receptor expression on 
endothelial cells. The same authors described the 
use of PEGylated, fluorescent and paramagnetic 
micelles (immuno-micelles) for imaging of mac-
rophages in atherosclerotic plaques [49]. Another 
approach followed was anchoring the antibody 
to a biotin–avidin complex [50–54]. This system 
allows the labeling of mixed micelles previously 
formulated combining the amphiphilic Gd com-
plex, the phospholipids and the TWEEN 80 
surfactant. The ex vivo images [50] and in vivo 
experiments confirmed that this kind of immuno-
micelles provides excellent validated in vivo 
enhancement of atherosclerotic plaques [51].
The same approach was used formulating 
polymerized vesicles by UV irradiation of a 
mixture of Gd-DTPA polymerizable lipid, a 
polymerizable biotinilated lipid and diacety-
lene phosphatidilcholine filler lipid [52–54], fol-
lowed by derivatization of the liposomes with 
LM609 monoclonal antibody capable of in vivo 
detection of tumor angiogenesis targeting the 
integrin a
v
b
3 
[54]. Similar antibody-conjugated 
paramagnetic polymerized liposomes were used 
to target the intercellular adhesion molecule-1, 
an endothelial leukocyte receptor on cerebral 
microvasculature in experimental autoimmune 
encephalitis [55]. 
Gadolinium-based paramagnetic supra-
molecular aggregates derivatized with bioactive 
peptides have essentially been developed in order 
to have selective contrast agents capable of visual-
izing neovascularization and angiogenic processes 
targeting a
v
b
3
 integrins or tumor proliferation 
Figure 2. Three routes for liposome labeling by bioactive molecules. According to route 1, a 
polyethylene glycol-phosphatidylethanolamine derivative monomer derivatized with a N-maleimido 
function is incorporated in the liposomes; after aggregate formation the externally exposed 
N-maleimido function reacts with the bioactive molecule to give the labeled supramolecular 
aggregate. In another approach (route 2), biotinylated aggregates are obtained by using a biotin-
bearing lipophilic tail in the surfactant mixture; successively, in a two-step process, the biotinylated 
supramolecular aggregates react with the protein avidin, then biotinylated peptides or antibodies 
interact in free avidin sites giving a noncovalently labeled compound. In the last case (route 3), 
labeled aggregates are obtained by co-assembling amphiphilic peptides and other surfactants. 
DSPE-PEG-N-maleimido: Polyethylene glycol-phosphatidylethanolamine derivative monomer 
derivatized with a N-maleimido.
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and metastasis targeting cellular receptors that 
are overexpressed by cancer cells. Some inter-
esting supramolecular constructs were ini-
tially developed by Stupp and co-workers by 
self-assembly of amphiphile RGD (Arg-Gly-
Asp) peptide sequences carrying a 1,4,7,10-tet-
raazacyclododecane-1,4,7,10-tetraacetic acid 
(DOTA)–Gd(III) complex [47,56]. These amphi-
philic  molecules self-assemble into spherical 
and fiber-like n anostructures [47]. Liposomes, 
conjugated with the a
v
b
3
-specific RGD peptide 
attached to PEG moieties, have been developed 
by Mulder and co-workers [57,58]. In vitro stud-
ies demonstrate that RGD-liposomes associate 
impressively with proliferating endothelial cells 
associated with cancer, they are internalized by 
the cells and localized to a perinuclear com-
partment. In vivo studies indicate that RGD-
liposomes are localized at the rim of the tumor 
with a distribution pattern that closely correlates 
with the position of angiogenic blood vessels in 
the tumor, which are found mainly at the rim. 
Moreover, these nanoparticles can be used, by 
MRI techniques, to non-invasively measure the 
efficacy of a ngiogenesis inhibitors during the 
course of a therapy [58].
Griffioen and co-workers used Anginex, 
a synthetic 33-mer angiostatic peptide that is 
capable of homing to activated endothelium, as 
targeting ligand [59]. Paramagnetic liposomes 
obtained by co-aggregation of Gd–DTPA lipid 
and maleimide–PEG2000–DSPE, derivatized 
with Anginex was studied in vitro on cell cultures 
and by MRI of cell pellets. The results indicate 
that Anginex is a potent ligand for the targeting 
of activated endothelial cells; in addition, the 
in vitro results showed a high specificity of the 
anginex-conjugated paramagnetic liposomes for 
endothelial cells that was confirmed by MRI.
Naposomes: a new class of  
peptide-derivatized target-selective 
multimodal nanoparticles
Multimodal supramolecular compounds that 
combine together imaging and therapeutic 
capabilities are the focus of intensive research 
for applications in the growing field of nano-
medicine. They offer the prospective to increase 
diagnostic accuracy and therapeutic effec-
tiveness, while minimizing side effects from 
t reatment [60,61]. 
In recent years we developed a new class of 
peptide-derivatized target-selective multimodal 
nanoparticles for imaging and therapeutic 
applications identified as ‘naposomes’.
Naposomes, with their micellar or liposomal 
structure can encapsulate active pharmaceutical 
principles and are promising candidates for such 
multifunctional therapeutic platforms since they 
are functionalized on their external surface with 
a reporter peptide to achieve specific and selective 
delivery to target cells and contain chelating agents 
able to give stable metal complexes for diagnostic 
applications such as imaging by MRI or positron 
emission tomography (PET) and scintigraphy. 
These materials are conveniently synthesized, 
and can be assembled to a range of sizes and com-
positions [62]. They are obtained by co-assembling 
two amphiphilic monomers: a first monomer con-
taining a hydrophobic moiety, a spacer and a bio-
active peptide having high affinity for membrane 
receptors expressed by target cells, and a second 
monomer based on the same hydrophobic moiety 
of the first monomer and containing a chelating 
agent able to complex several metal ions with 
high stability. Figure 3 shows the two amphiphi-
lic monomers and supramolecular aggregates that 
can be obtained when monomers are combined 
at the chosen molecular ratio in water solution. 
Several parameters such as pH, ionic strength, 
monomer composition and formulation pro-
cedure (dissolution in buffered solution or well-
assessed procedures based on sonication and 
extrusion) can influence the size and shape of the 
aggregates, which includes: spherical or ellipsoidal 
micelles, cylindrical or elongated micelles, open 
bilayers or liposomes. All these supramolecular 
aggregates are characterized by the presence of the 
bioactive peptide well exposed on the external sur-
face of the aggregate, while the chelating agents, 
or their metal complexes, remain on the aggregate 
hydrophilic shell. Only in the case of liposomes 
are peptides and chelating agents equally divided 
between the external aggregate surface and the 
inner aqueous compartment. 
The hydrophobic moieties present on both 
monomers are based on one or two hydrocarbon 
chains, saturated hydrocarbon chains with 18 
 carbon atoms are the most widely hydrophobic 
moieties used in naposome preparation. The 
spacer introduced, in the first monomer, between 
the bioactive peptide and the hydrophobic moiety 
is very important to allow the peptide to remain 
well exposed on the external surface of the aggre-
gate and to maintain its high binding affinity, in 
the nanomolar range, to the membrane receptors 
expressed by target cells. Oxoethylene and poly-
ethylene linkers of different MW have been ten-
titavely used to define the best length to preserve 
peptide exposition and bioavailability.
Key Term
Multimodal nanoparticles: 
Nanoparticles derivatized  
with a drug and a contrast  
agent for different applications, 
and with bioactive or  
protective compounds to 
improve their in vivo 
biodistribution and stability. 
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The spacer in the second monomer is usu-
ally a lysine residue. It is introduced between the 
hydrophobic moiety and the chelating agent, for 
synthetic reasons. In fact, the lysine residue, with 
its three active functions, can be linked through 
the carboxy function to a solid support allowing 
solid-phase synthesis of the entire monomer by 
selective reactions of the a and e amino groups 
with the hydrophobic moiety and the chelating 
agent, respectively.
The chelating agents used in naposome prepa-
ration are branched or cyclic polyamino-poly-
carboxy ligands: DTPA and its glutamic analog 
DTPAGlu are branched ligands with five or six 
carboxylic functions, respectively; DOTA is a 
cyclic chelating agent with four carboxylic func-
tions and four amino groups. In all chelating 
agents, one carboxylic function is used to link 
the chelating agent to a lysine side chain in the 
amphiphilic monomer, while the other carbox-
ylic functions and the amino groups form the 
coordinative set for several metal ions, thus giv-
ing thermodynamically stable and kinetic inert 
metal complexes. Metal complexes of Gd(III) for 
MRI applications, of 111In(III) for scintigraphic 
imaging and of Ga(III) for PET tomography, 
have been obtained. 
Until now, naposomes have been prepared 
by using three different peptides: CCK8 [63–74], 
7-14-bombesin (BN) [75] and octreotide [76,77]. 
These peptides are well known endogenous 
(CCK8 and BN) or artificial (octreotide) ligands 
for membrane receptors overexpressed by cells of 
several human cancers. 
CCK8 corresponds to the eight-residue 
C-terminal end of the cholecystokinin pep-
tide hormone [78], and has been widely studied 
for its high binding affinity, in the nanomolar 
range, towards the two cholecystokinin recep-
tors, CCK1-R and CCK2-R [79]. These recep-
tors represent very important targets for selective 
therapeutic delivery being found overexpressed 
in pancreatic cancers, meningiomas and neu-
roblastomas (CCK1-R) and in small-cell lung 
cancer, colon and gastric cancers, medullar thy-
roid carcinomas and stromal ovarian tumors 
(CCK2-R) [80,81]. Moreover, the NMR solution 
structures of the complexes between CCK8 and 
Figure 3. Representation of two monomers: one containing a peptide moiety and the other containing the chelating 
agent. By combining the two monomers, mixed aggregates with different size and shape are obtained, as indicated on the right of the 
figure. In the two frameworks, the peptide sequences (octrotide, 7-14-bombesin and CCK8) and the structure of chelating agents used 
for naposomes preparation are reported.
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receptor fragments have also been reported; ana-
lysis of the structure indicates that modification 
on the N-terminus of CCK8 does not interfere 
with the binding region [82]. This hypothesis has 
been widely confirmed by the behavior of CCK8 
derivatives containing bulky substituents on the 
N-terminus: CCK8-modified compounds that 
contain radioactive metal ions complexed by 
branched or cyclic chelating agents introduced 
on the peptide N-terminus, present receptor-
binding properties in the same nanomolar 
range of the unmodified CCK8 peptide and 
have been proposed as target-selective contrast 
agents for nuclear medicine techniques [83]. 
7-14-bombesin is the C-terminal fragment of 
BN peptide and it binds members of the BN 
receptor family that consists of four receptor 
subtypes including the neuromedin B recep-
tor, the gastrin-releasing peptide receptor, the 
orphan receptor subtype, and the amphibian 
receptor [84–87]. The expression of gastrin-
releasing peptide receptors is found in several 
human cancer cell lines, such as prostate, breast 
cancer, small-cell lung cancer and ovarian can-
cer [88–90]. Also 7-14-BN derivatives modified 
on the N-terminus with radioactive metal com-
plexes are used as target-selective contrast agents 
for scintigraphic and PET images, while peptide 
derivatives containing b-emitting radio nuclides 
on the N-terminus have been proposed as 
target-selective radiotherapeutics [91]. octreotide 
is a well known synthetic cyclic peptide widely 
used as an in vivo stable somatostatin analog [92]. 
It binds the somatostatin receptors (SSTRs), 
in particular the SSTR2 and SSTR5 receptor 
sub-types [93,94] and is pharmacologically used 
as a somatostatin analog in many therapeutic 
pro cedures that need somatostatin, such as pitu-
itary adenomas. octreotide derivatives labeled 
with 111In complexed by DTPA linked to pep-
tide N-terminus (Octroscan®) are clinically used 
as scintigraphic contrast agents [95] to evidence 
the overexpression of SSTRs in several human 
tumors such as neuroendocrin tumors, tumors of 
the nervous system, lymphomas and some breast 
cancers [96–99]. 
The membrane receptor overexpression in sev-
eral clinically relevant human tumors together 
with the finding that these peptides can be 
modified on their N-terminal end without 
substantial loss of their receptor-binding affin-
ity, suggested the use of these three peptides in 
naposome development. 
Other endogenous peptides able to target 
membrane receptors overexpressed in patho-
logical conditions could be explored to develop 
new target-selective nanoparticles for delivery of 
therapeutic and/or contrast agents. Neurotensin, 
vasointestinal peptide, neuropeptide Y, their 
stable fragments or their peptide analogs act-
ing as agonist or antagonists seem the best 
candid ates to develop other peptide-modified 
s upramolecular aggregates [100].
Four different classes of naposomes have been 
developed to date. They are based on the use 
of different amphiphilic monomers, as sche-
matized in Figure 4. In any case, amphiphilic 
monomers are synthesized by using solid-phase 
procedures. The peptide-containing monomer is 
synthesized starting from the C-terminal end: 
the last amino acid in the peptide sequence is 
bound to the resin acting as solid support, then 
9-fluorenylmethyloxycarbonyl (Fmoc) deprotec-
tion and coupling steps are performed accord-
ing to classic procedures for peptide synthesis in 
solid phase and using the Fmoc/tert-butyl chem-
istry. After the peptide synthesis is complete, 
and analytically certified, one or more oxoeth-
ylene spacers or PEG derivatives are linked to 
the peptide N-terminus, using Fmoc–amino–
oxoethylene- or Fmoc–amino–PEG-protected 
derivatives containing a carboxylic function 
that is activated in situ by using classic coupling 
reagents. After Fmoc deprotection the hydro-
phobic moiety is bound by using an aliphatic Figure 4. Four classes of naposomes. 
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amine linked to a succinic spacer. At the end of 
the solid-phase synthesis the monomer is cleaved 
from the resin and purified by HPLC. In addi-
tion, the second monomer is prepared by using 
solid-phase methods: a lysine residue, containing 
orthogonal protecting groups on the two amino 
functions, is linked through the carboxylic func-
tion to the resin, then the a and e lysine amino 
groups selectively react with the hydrophobic 
moiety and the chelating agent, respectively. 
Chelating agents containing all the carboxylic 
acid functions, except that used to bound the e 
lysine amino function (which is protected as a 
tert-butyl ester) are used. 
The two monomers are combined in mixed 
supramolecular aggregates in buffered water 
solution, simply mixing them in solution or 
by using classical procedures to prepare lipo-
somes based on the preparation of a lipid film 
in organic solvent, the film dissolution in buff-
ered water solution followed by sonication and 
extrusion procedures. The two monomers are 
combined together using a defined molecular 
ratio, usually the chelating agent-containing 
monomer is the more abundant monomer and 
the peptide-containing monomer is present in a 
lower amount, between 3 and 30% of the total. 
In some cases other phospholipids are also added 
in the final composition. 
	n First-class naposomes
The first class of naposomes is based on two 
amphiphilic monomers containing a single-
tailed hydrophobic monomer with 18 carbon 
atoms, the CCK8 peptide, in the first monomer, 
as a target-selective tool, and DTPAGlu as che-
lating agent, able to complex paramagnetic Gd 
ions, in the second monomer [63,64]. They have 
been prepared in order to obtain mixed micelles 
to be used as new potential target-selective con-
trast agents in MRI. This was the first attempt 
to form a supramolecular aggregate containing a 
bioactive molecule able to deliver a large amount 
of paramagnetic Gd ions to a specific place, that 
is, where tumor cells are present. 
The two monomers C18DTPAGlu(Gd) and 
C18L×CCK8 (× = 2, 5) are schematized in the 
framework of Figure 5. Two different peptide 
monomers have been synthesized, one in which 
the linker between the alkyl chain and the pep-
tide is composed by two oxoethylene moieties 
and a glycine residue (C18L
2
CCK8), and the 
other with a larger number (five) of oxoethylene 
linkers (C18L
5
CCK8). The mixed aggregates 
(Figure 5, right side), obtained by combining the 
two monomers in a molar ratio between 95:5 and 
70:30, as well as the pure C18DTPAGlu aggre-
gate, in the presence and absence of Gd(III), 
have been fully characterized by surface tension 
measurements, FT-PGSE-NMR, fluorescence 
quenching, fluorescence spectroscopy, and small-
angle neutron scattering (SANS) measurements. 
In all cases the two monomers, C18DTPAGlu 
(or C18DTPAGlu([Gd]) and C18L
2
CCK8, 
form mixed spherical micelles (critical micelle 
concentration [cmc] ~5 × 10–5 mol kg-1) with an 
external shell of approximately 21 Å, an inner 
core of approximately  20 Å and an aggregation 
number, N
agg
, of approximately 65. Both the 
DTPAGlu(Gd) complexes and the CCK8 pep-
tides point toward the external micelle surface. 
Formation of mixed aggregates is confirmed by 
self-diffusion experiments and SANS measure-
ments. In fact, the NMR signals of the two mono-
mers never showed a multi-exponential decay, 
indicating that the two monomers co-micellize 
and, consequently, diffuse together. Moreover, 
the magnitude of the SANS scattering profile of 
the C18DTPAGlu–C18LxCCK8 system with 
respect to the pure C18DTPAGlu system showed 
a significant increase in intensity, suggesting 
the formation of mixed micelles (Figure 5a). 
Mixed micelles based on C18L
5
CCK8 showed 
similar properties with respect to micelles based 
on C18L
2
CCK8, although the hydrodynamic 
radius was found to be a slightly larger 37 Å. 
This behavior is due to the C18L
5
CCK8 inser-
tion in the mixed aggregates that promotes the 
formation of more elongated micelles. The SANS 
data in this case show a reasonably good fit, also 
using an ellipsoid model. Moreover, the struc-
tural data ana lysis suggests that the bioactive 
CCK8 peptide is not completely exposed on the 
external micelle surface in systems containing 
C18L
2
CCK8. The length of the oxoethylene 
linkers and glycine residues could be too short 
to allow an efficient exposure of CCK8 at the sur-
face. According to crystallographic data of PEG, 
a chain of two oxoethylene linkers has a linear 
dimension of approximately 12 Å; whereas, the 
thickness of the hydrophilic DTPAGlu shell of 
the mixed micelle is approximately 18 Å. Hence, 
a considerable part of the bioactive peptide in 
C18L
2
CCK8 is probably hidden among the 
DTPAGlu moieties, reducing the chance that the 
aggregates could bind to the membrane proteins 
overexpressed by tumor cells. In contrast, in the 
case of mixed micelles containing C18L
5
CCK8 
there is a complete exposure of the CCK8 pep-
tide externally to the micelles. The length of 
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the spacer (five oxoethylenes) is approximately 
30 Å, a value quite a bit larger than the shell 
thickness. Substantial structural differences 
were not found when the C18DTPAGlu or its 
Gd complex C18DTPAGlu(Gd) were used for 
aggregate preparation even if the C18DTPAGlu 
monomer contains five negative charges on the 
chelating agent, while the Gd monomer com-
plex remains with only two negative charges. The 
measured values for relaxivity, in a saline medium 
at 20 MHz proton Larmor Frequency and 25°C, 
for Gd complexes in the pure C18DTPAGlu(Gd) 
micelles and for the mixed systems are 17.5 and 
18.7 mM-1s-1, respectively (Figure 5b). These val-
ues are in good agreement with those reported 
in the literature for supramolecular aggre-
gates obtained by self-assembling mono-tailed 
amphiphilic monomers and indicate a large 
enhancement in comparison with that of iso-
lated DTPAGlu(Gd) complex in water s olution 
(6.2 mM-1s-1). 
Receptor-binding ability of micelles belong-
ing to the first class of naposomes was evalu-
ated by standard nuclear medicine experiments 
(Figure 5c). Micelles obtained by co-assembling 
C18DTPAGlu/C18L
5
CCK8 in a 70:30 molar 
ratio, are labeled with the g-emitting radio-
nuclide 111In. This metal ion is complexed by 
DTPAGlu chelating agent by incubation of 
preformed micelles, at aggregate concentrations 
above the cmc to avoid presence of free mono-
mers in solution, with InCl
3
 at room tempera-
ture. According to classical labeling procedures 
used in nuclear medicine techniques, only a small 
Figure 5. First class of naposomes, based on single-tailed monomers. Schematic representation of
C18DTPAGlu(Gd) and C18LxCCK8 (x = 2, 5) monomers. Right-hand side of figure: schematic representation of micelles
obtained by mixing together the two monomers in a 70:30 molar ratio is reported. In the table, structural data and relaxometric 
properties are summarized. Bottom of figure: (A) scattering intensity profile for C18DTPAGlu(Gd) and C18L
2
CCK8 binary systems and 
C18DTPAGlu(Gd)/C18L
2
CCK8 ternary system; (B) NMR dispersion profiles of C18DTPAGlu(Gd)/C18L
2
CCK8 (○), C18DTPAGlu(Gd) (•) 
and DTPAGlu(Gd) complex (▲) at pH 7.4 and 298 K, normalized to 1 mM concentration of Gd(III) ion; (C) binding assays of 
radio-labeled mixed aggregates C18DTPAGlu/C18L
5
CCK8 on A431 cells overexpressing CCK2-R at 4 and 37°C.
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percentage of the DTPAGlu chelating agents are 
present on the hydrophilic monomer complexes; 
despite this, in radionuclides the total amount 
is enough to study the binding properties of 
the entire aggregate. Binding experiments are 
performed on A431 (a human epidermoid car-
cinoma cell line) cultured cells overexpressing 
the CCK
2
-R by stable transfection and compared 
with control cells. Since a certain degree of non-
specific binding and internalization of the aggre-
gates was expected, experiments are performed 
both at 4°C (in order to block cellular meta-
bolic processes such as nonspecific internaliza-
tion) and at 37°C (to keep metabolic processes 
active). Similar results are obtained under the 
two experimental conditions indicating receptor 
targeting specificity and negligible nonspecific 
binding and i nternalization (Figure 5c). 
It is worth noting that, in general, micelles 
respond rapidly to changes in their environment, 
while bilayers are much more sluggish. These 
results are of crucial importance for the use of 
this class of target selective contrast agents from 
the clinical point of view. In fact, in order to 
preserve the high relaxivity and the target selec-
tivity, the supramolecular aggregates should 
remain in a compact-defined structure during 
the imaging ana lysis. The aggregates should not 
collapse upon 1000–10,000-fold dilution once 
the stock solution of the contrast agent is injected 
in the human body. Concerning this issue, the 
use of micelles, especially those that are based 
on single-tailed amphiphilic monomers that 
give aggregates with high cmc, could be inap-
propriate. An alternative approach to prepare 
physiologically stable aggregates, that do not 
disaggregate even at high dilution, include the 
use of polymerized nanoparticles. They could 
be obtained by using polymerizable amphiphilic 
monomers: 10,12-pentacosadiynoic acid (PDA)-
DTPAGlu(Gd) and PDA-L2-CCK8 contain 
the PDA as hydrophobic moiety, with two C≡C 
triple bonds, that can be irradiated by UV light 
to induce chain–chain polymerization in stable, 
covalently bound, aggregates [72]. These systems 
show an improved physical stability, originated 
from the increased rigidity and were able to 
avoid, to some extent, RES uptake. Aggregates 
obtained by mixing together PDA-DTPAGlu, 
or its Gd(III) complex, and PDA-L2-CCK8 in 
a 70:30 molar ratio before and after UV polym-
erization have been structurally characterized by 
means of SANS. Micelle aggregates have quite 
an elongated shape (with the axes ratio ranged 
between 2 and 3), and dimensions of semiaxis 
ranged between 10 and 30 Å; relaxivity value 
for each Gd complex, measured at 20 MHz and 
298 K, are approximately 12 mM-1s-1.
	n Second-class naposomes
The possibility of using Gd-labeled micelles for 
imaging applications or as general micelles for 
drug delivery, depends on the degree of stabil-
ity in the body of the aggregate loaded with the 
drug or with the contrast agent, relative to the 
cmc. The first class of naposomes is based on 
micelles obtained by co-assembling monomers 
with only one hydrophobic chain. Upon dilution 
in the blood following injection, these aggregates 
may not be sufficiently stable and disassemble 
immediately following administration. Hence, 
there is a need to find a new class of surfactant 
molecules able to form more stable aggregates, 
for example micelles with lower cmc values, or 
stable liposomes. 
The second class of naposomes is based on 
amphiphilic monomers containing the peptide 
or the chelating agent bound to two hydrocar-
bon chains as the hydrophobic moiety (Figure 6). 
These double-tailed monomers could give more 
stable nanoparticles; moreover, while single-
chain monomers could disrupt biological mem-
branes giving strong hemolytic effects, mono-
mers bearing two hydrophobic tails, do not 
present hemolytic effects and toxicity problems 
due to their higher similarity with membrane 
phospholipids with respect to single-chain 
amphiphiles [101].
We reported supramolecular aggregates, basi-
cally constituted by an amphiphilic monomer in 
which the chelating agent (DTPAGlu, DTPA 
or DOTA) moiety is bound to a hydrophobic 
double-tail, with each hydrocarbon chain with 
18 carbon atoms. The amphiphilic molecule 
(C18)
2
DTPAGlu, as free base or as Gd complex, 
behaves as an anionic surfactant, and extruded 
at physiological pH, self-assembles in different 
aggregates (micelles with an elongated shape, 
and open bilayers, that could form stable lipo-
somes) [65]. Variation of pH has a drastic effect on 
the size distribution of the aggregates: a micelle-
to-vesicle transition is observed by decreasing 
the pH value from 7.4 to 3.0. In detail, micelle 
formation occurs in the pH range between 7.4 
and 5.0, owing to the high negative charge of the 
surfactant headgroup, which causes strong head-
group–headgroup repulsions. A decrease of the 
pH (5.0–4.5) causes a protonation of the carboxy-
lic functions and a decrease of the electrostatic 
repulsion between the headgroups, favoring the 
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formation of thread-like micelles. Finally at pH 3, 
where all carboxylic groups are fully protonated, 
the formation of large, low curvature aggregates 
such as bilayer structures or liposomes is pro-
moted. The effect of ionic strength on the systems 
of (C18)
2
DTPAGlu in the absence and in pres-
ence of Gd(III) has been investigated at pH 7.4. In 
both cases any substantial effect of sodium chlo-
ride salt addition has not been revealed. Relaxivity 
values of (C18)
2
DTPAGlu(Gd) aggregates at 
pH 7.4 in the presence and absence of sodium 
chloride at physiological ionic strength are 21.5 
and 24.0 mM-1s-1, respectively.
Similar behavior has been found in the case 
of amphiphilic monomers containing DTPA or 
DOTA chelating agents, even if the negative 
charges diminish, going from five for DTPAGlu 
to four for DTPA and three for DOTA. After 
Figure 6. Second class of naposomes, based on double-tailed monomers. The upper side of the figure shows a schematic
representation of the single monomers and of liposomes obtained by sonication and extrusion procedures. The lower shaded part of 
the figure shows selected results from structural and biological studies of naposomes labeled by CCK8 (1), bombesin (BN) (2) and 
octreotide (3) peptides. CCK8: (1A) g-camera image (dorsal view) obtained prior to dissection of one of the animals 18 h after injection 
of radiolabeled aggregates clearly shows higher concentration of the radiolabel in the receptor positive xenograft (+, left flank) 
compared with the control tumor (-, right flank). These differences were statistically significant when comparing data from the five 
animals (paired t-test, p = 0.01). (1B) Cytotoxicity of liposomal doxorubicin (DXR) against human carcinoma cells. A431 cells were 
incubated with CCK8/DOTA-DXR and DOTA-DXR at different concentration ranging between 0 and 1000 ng/ml at 37°C. After 8 h, the 
medium was removed and after additional 72 h, an MTT assay was performed. BN: (2A) In vitro binding assays on PC-3 cell lines 
overexpressing the GRP at 37°C, at different time points of 111In-(C18)
2
DOTA /(C18)
2
L
5
- [7-14] BN (90/10) (dark blue bars) with respect 
to the corresponding aggregates in which the BN peptide is replaced by the BN scrambled peptide (light blue bars) and to the self-
assembled 111In-(C18)
2
DOTA (gray bars). (2B) g-camera images (ventral view) at different times after injection of 111In-(C18)
2
DOTA/
(C18)
2
L
5
 [7-14] BN naposomes. octreotide: (3A) Scattering cross sections of (C18)
2
DTPAGlu(Gd)/(C18)
2
L
5
-Oct (■); (C18)
2
DTPA(Gd) /
(C18)
2
L
5
-Oct (□) and (C18)
2
DOTA(Gd)/(C18)
2
L
5
-Oct (•) obtained at 25°C from small-angle neutron scattering experiments; (3B) NMR 
dispersion profiles of (C18)
2
DTPAGlu(Gd)/(C18)
2
L
5
-Oct (□), (C18)
2
DTPA(Gd)/(C18)
2
L
5
-Oct (■) and (C18)
2
DOTA(Gd) /(C18)
2
L
5
-Oct (•) at 
pH = 7.4 and 298 K, normalized to 1-mM concentration of Gd(III) ion. 
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Gd complexation, DTPA- and DOTA-chelating 
agents keep one and zero residual charges, respec-
tively. Similarly to the pH effect observed for 
DTPAGlu, in this case a progressive decrease of 
the negative charges in the surfactant headgroup 
lead to a decrease of the electrostatic repulsion, 
favoring the f ormation of bilayer structures or 
liposomes [77].
In order to prepare target-selective nanoparti-
cles, mixed supramolecular aggregates have been 
developed by adding a small amount of peptide-
containing amphiphilic monomer. Several pep-
tide monomers, in which three different bioac-
tive sequences (CCK8, 7-14-BN or octreotide) 
and spacers of different length between the 
peptide and the alkyl chains have been used. 
The spacer length represents a critical point, in 
fact, as mentioned previously, the spacer should 
be long enough to assure an efficient exposure 
of the peptide beyond the surface of the aggre-
gates and reduce potential hindrance to its spe-
cific binding activity, and at the same time, short 
enough to promote liposome formation. 
Second-class naposomes labeled by CCK8 
peptide were prepared by starting from three pep-
tide monomers: one in which the spacer consists 
of five units of ethyleneglycol, (C18)
2
L
5
CCK8 
[66,68,71], one in which the spacer is a PEG chain 
with an average molar weight of 2000 g mol-1 
(PEG
2000
), (C18)
2
PEG
2000
CCK8 [70] and one 
containing the DSPE–PEG
2000
 moiety (DSPE–
PEG
2000
-CCK8) [67]. 
(C18)
2
L
5
CCK8, is able to self-assemble 
spon taneously in well-ordered nanostructures 
in aqueous solution [102] and characterized by 
water-exposed CCK8 peptide in b-sheet confor-
mation. They are able to encapsulate anticancer 
drugs such as DOX, and could be employed for 
target-selective drug delivery on a biological tar-
get, through the bioactive peptide exposed on the 
external surface. 
Mixed aggregates (C18)
2
DTPAGlu(Gd)/
(C18)
2
L
5
CCK8 (70:30 monomer ratio) are char-
acterized by the presence of bilayer structures 
(open bilayers and liposomes) under physiologic 
conditions [68]. The relaxivity value of each Gd 
complex in liposomes (hydrodynamic radius of 
~300 Å) was of approximately 21.0 mM-1s -1. This 
relaxivity value represents the sum of both inner 
and outer Gd complexes because of the high 
membrane water permeability [66]. Similar relax-
ivity behavior has been obtained for aggregates in 
which the (C18)
2
L
5
CCK8 monomer is replaced 
by (C18)
2
PEG
2000
CCK8. From a structural 
point of view, mixed aggregates based on CCK8 
peptide ([C18]
2
DTPAGlu/[C18]
2
PEG
2000
CCK8) 
in a 70:30 ratio, appear in solution as a combi-
nation of rod-like micelles (radius of ~40 Å and 
length >700 Å), open bilayer fragments (thick-
ness ~65 Å) and liposomes [70]. Therefore, when 
the L
5
 spacer is replaced by PEG
2000
, there is an 
increase in micelle population:PEG-contain-
ing monomers, which also show a lower ten-
dency to form liposomes in comparison with 
L5-containing m onomers after sonication and 
extrusion processes. 
Stable lamellar aggregates were obtained in the 
case of samples containing only DSPE–PEG
2000
–
CCK8, or a quantity of (C18)
2
DTPAGlu(Gd) 
up to 50% [67]. By increasing the amount of 
(C18)
2
DTPAGlu(Gd) in the aggregate, a lamel-
lar aggregates-to-rod-like micelle transition is 
observed. This structural transition can probably 
be attributed to the presence of the uncharged 
peptide monomer that interposes between the 
charged headgroups of the chelating agent 
monomer. The proton relaxivity was exactly the 
same (17.2 mM-1s -1) for both lamellar aggregates 
and rod-like micelles though in the two cases its 
value is the result of the co mbination of different 
local and global contributions.
In vitro and in vivo selective binding activity 
and biodistribution of mixed aggregates deriva-
tized by CCK8 were studied by nuclear medicine 
experiments [70]. For this purpose the Gd ion 
was replaced with a 111In g-emitting radio isotope, 
as reported above for first-class naposomes. 
Mixed aggregates based on the CCK8 peptide 
([C18]
2
DTPAGlu/[C18]
2
Peg
2000
CCK8 in a 
70:30 ratio) that appear in solution as a com-
bination of rod-like micelles, open bilayer and 
liposomes, present the CCK8 bioactive peptide 
well exposed on the external aggregate surface, 
as indicated by fluorescence measurements [70]. 
This feature should make possible the selective 
target of these nanocarriers towards the cholecys-
tokinin receptors overexpressed by the cancerous 
cells. In fact, 111In-labeled aggregates show pref-
erential binding to A431 cells overexpressing the 
CCK
2
-R by transfection compared with control 
cells both at 4°C and at 37°C. In vivo biodistri-
bution experiments show that overall retention 
of the radiolabel in the experimental animals at 
18 h is very high, with essentially no excretion 
of the starting radioactivity over the observa-
tion period. All organs show significant reten-
tion of radio activity, although this is particularly 
elevated in organs with a RES such as the liver 
and spleen. Direct comparisons, within the same 
animal of the biodistribution data show that 
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receptor-positive xenografts were always higher 
in radioactivity retention than their respective 
controls. The average enrichment factor in radio-
activity of the CCK
2
-R positive xenografts was 
found to be 48 ± 21% (Figure 6.1a) Any acute 
toxicity following the intravenous administra-
tion of the compound is observed during the 
observation period. Moreover, the drug loading 
capability of the aggregates and their drug effi-
ciency on the target cells was reported by using 
the cytotoxic DOX drug. Incubation of receptor 
positive and control cells with peptide-contain-
ing aggregates filled with DOX showed signifi-
cantly lower cell survival in receptor-expressing 
cells with respect to the control, for samples 
incubated in the presence of DOX. Comparable 
results were obtained with mixed liposomes, pre-
pared by combining together, in a 90:10 molar 
ratio, (C18)
2
DOTA–(C18)
2
L
5
CCK8. The DOX 
loading content was above 95% of the total drug 
and the corresponding drug:lipid w/w ratio was 
0.134. The cellular uptake of the targeted lipo-
somal DOX CCK8–DOTA-DOX with respect 
to the self-assembled, nonspecific, liposomal 
DOX DOTA-DOX has been evaluated by the 
use of flow cytometry assays (Figure 6.1b). The 
cell-associated DOX on A431 and HUVEC cells 
for peptide-derivatized liposomes was 70- and 
8-fold higher than that for nontargeted lipo-
somes, respectively, indicating that the bioac-
tive CCK8 peptide is able to enhance the DOX 
uptake into the A431 carcinoma cells and, to a 
lower extent, in the endothelial HUVEC cells. 
Cells incubated with peptide-derivatized lipo-
somes showed significantly lower cell survival 
compared with nontargeted liposomes, in the 
presence of drug amounts ranging between 250 
and 1000 ng/ml [74].
In vitro and in vivo binding assays by nuclear 
medicine were also carried out on second-
class naposomes based on (7-14)-BN peptide 
([C18]
2
DOTA/[C18]
2
-spacer-[7-14]-BN) [75]. 
The peptide in the amphiphilic monomer is 
spaced by the lipophilic moiety through eth-
oxylic spacers of different length: a shorter 
spacer with five units of dioxoethylene moieties 
in (C18)
2
L
5
-peptide, or a longer spacer con-
sisting of a PEG
3000
 residue in (C18)
2
PEG
3000
-
peptide. Structural characterization by SANS 
and dynamic light scattering (DLS) techniques 
indicate that, independently from the amount 
(<10%) of the peptide-containing monomer in 
the final composition, the predominant aggre-
gates are liposomes of similar shape and size 
with a hydrodynamic radius R
h
 of approximately 
200 nm and bilayer thickness, d, of 4 nm. This 
structure is slightly different from that observed 
for CCK8 aggregates described above in which 
DTPAGlu amphiphilic monomer is present, 
and highly polydisperse aggregates are found. 
This behavior could be explained on the basis 
of the lower negative charge (-3) of DOTA 
with respect to DTPAGlu (-5). In vitro data, 
reported in Figure 6.2a, show specific bind-
ing of the 111In-(C18)
2
DOTA–(C18)
2
L
5
-(7-14) 
BN-containing aggregates in receptor-expressing 
cells. Instead, the presence of PEG3000 units 
on the external liposomal surface, could hide 
the peptide and prevent the receptor binding. 
In fact, too high a surface coverage could be 
unfavorable for targeting purposes, since it may 
prevent the contact between the peptide and the 
membrane receptors [75].
In vivo experiments using 111In-(C18)
2
DOTA/
(C18)
2
L
5
-(7-14)-BN show the expected bio-
logical behavior of aggregates of such size and 
molecular composition preliminarily confirm 
the ability to specifically target and concentrate 
in receptor expressing xenografts (Figure 6.2b). 
In fact it can be observed that an increase in 
concentration of the targeting agent aggregate in 
the tumors compared with controls, at the 48 h 
time point evaluated (2.4% ID/g vs 1.6% ID/g).
Second-class naposomes based on an octreo-
tide peptide were also prepared as diagnostic tools 
in MRI [77]. They present high relaxivity values 
typical of the new generation of MRI contrast 
agents, based on nanoparticles obtained by lipo-
philic Gd(III) complexes [103,104]. Naposomes 
were formulated by mixing two amphiphilic 
monomers. The first monomer (C18)
2
L
5
-Oct 
contains two C18 hydrophobic moieties bound 
to the N-terminus of the cyclic peptide octreo-
tide, and spaced from the bioactive peptide by five 
units of dioxoethylene linkers, while the second 
monomer is (C18)
2
DTPAGlu or (C18)
2
DTPA or 
(C18)
2
DOTA. The number of oxoethylene link-
ers was selected, according to biological results 
previously obtained on similar aggregates deriva-
tized with CCK8 [70] or 7-14-BN [75], in order to 
favor a good exposure of octreotide on the external 
aggregate surface. The presence of a small amount 
of amphiphilic octreotide monomer exposed on 
the aggregate surface, as indicated by fluorescence 
studies, give the nanoparticles a potential bind-
ing selectivity toward the somatostatin SSTR2 
receptor subtype. Structural differences between 
the aggregates formulated by starting from the 
three chelating agents, or from their Gd com-
plexes, have been observed and rationalized by 
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SANS measurements, on the basis of their dif-
ferent residual charge (Figure 6.3a). According 
to other reported systems [65], a decrease of the 
negative charges on the aggregate surface pro-
motes a micelle-to-vesicle transition going from 
two for DTPAGlu(Gd) to one for DTPA(Gd) 
and zero for DOTA(Gd). A decrease in relax-
ivity values (from r
1p
 = 17.6–10.0 mM-1s-1), due 
to an increase of water exchange lifetimes 
(τ
M
) of the monoamides, can be observed in 
Figure 6.3b going from (C18)
2
DTPAGlu(Gd)- to 
(C18)
2
DOTA(Gd)-containing ternary systems. 
	n Third-class naposomes
A further upgrade of the naposomes supramo-
lecular system is obtained by designing and 
synthesizing new monomers with an ‘upsilon’ 
shape and indicated as MonY (Figure 7). This 
monomer combines in the same molecule all 
the three fundamental tasks that are required to 
obtain target-selective nanoparticles for delivery 
of drugs and contrast agents: 
n	The bioactive peptide;
n	The chelating agent;
n	The hydrophobic moiety;
The MonY monomer is based on a lysine residue 
derivatized on its three reactive functions with: 
n	DTPAGlu or DOTA chelating agent on the 
side-chain e-amino group;
n	CCK8 or octreotide peptide on the lysine 
 carboxylic function; 
n	The hydrophobic moiety containing two 18 
carbon-atom alkyl chains on the lysine 
a-amino group [69,76].
DTPAGlu was selected as chelating agent in 
CCK8-MonY monomer [69], while DTPAGlu 
and DOTA were chosen for octreotide-
MonY [76]. According to DLS and SANS data, 
MonY molecules are always able to form ellipsoi-
dal micelles and bilayer structures when in their 
uncomplexed form. On the contrary, monomers 
based on DOTA are not able to self-aggregate 
when complexed with Gd(III) ions. The com-
plete loss of charges on the Gd–DOTA complex 
produces a remarkable reduction of the anionic 
character of the amphiphilic monomer, which is 
no longer able to aggregate. 
The two CCK8-MonY and octreotide-MonY 
based on DTPAGlu chelating agent, self-aggre-
gate in buffered water solution giving ellipsoidal 
micelles in which the ratio between micelle axes 
is approximately 2.7 and the aggregation number 
N
agg
 is approximately 30 (Figure 7). There were no 
detectable differences in the aggregation behav-
ior between MonY and MonY(Gd), indicating 
that the presence of metal ions, and therefore the 
reduction of the net charge, does not substantially 
influence the aggregation behavior. Aggregate 
shape and size of the two MonY are similar to 
micelles obtained by co-aggregation of two mono-
mers, one bearing the Gd complex and the other 
the bioactive peptide, and both containing one 
single hydrocarbon C18 chain (first-class napo-
somes). The ellipsoidal rather than the spherical 
shape of the previously reported system is the most 
evident structural difference; moreover the pres-
ence of the double hydro carbon chain gives higher 
micelle stability in water solution as indicated 
by lower cmc values. In the case of aggregates 
obtained by using CCK8-MonY, fluor escence 
studies and circular dichroism experiments indi-
cate the complete exposure of CCK8 peptide on 
the micelle surface, and the predominant presence 
of an antiparallel b-sheet peptide conformation 
characterized by a b-like turn. The high relaxiv-
ity values of CCK8-MonY and octreotide-MonY 
micelles (r
1p
 = 15.0 mM-1s-1 and r
1p
 = 13.9 mM-1s-1 
at 20 MHz and 25°C, respectively), indicate these 
aggregates as p romising target-selective MRI 
c ontrast agents. 
In order to obtain multimodal liposome 
aggregates for simultaneous drug and contrast 
agent delivery, MonY  has been mixed with dio-
leoylphosphatidylcholine (DOPC), a phospho-
lipid that is one of the main lipids composing the 
cell membrane. DOPC self-assembles in lipo-
somes and these structures preserve shape and 
characteristics on addition of MonY or MonY (Gd) 
up to an amount of 20% of the total concentra-
tion [69]. The thickness of the liposome bilayer 
is measured by SANS to be 30–40 Å, whereas 
cryo-transmission electron microscopy images 
show that the liposome diameter ranged between 
50 and 150 nm (Figure 7; right). Upon raising 
the amount of MonY, in the mixed aggregated 
to 50%, the liposome structures are destabilized 
leading to bilayers that coexist with rod-like 
micelles, as indicated by scattering techniques. 
Relaxivity values of each Gd complex in DOPC–
MonY(Gd) liposomes (80:20 in molar ratio) is 
12.7 mM-1s-1, at 20 MHz and 25°C. 
As reported in Figure 7 aggregates belonging 
to the third class of naposomes have been tested 
for their targeting behavior. Results obtained 
by g-counts on A431 cells and compared with 
control cells after incubation with third-class 
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Figure 7. Third-class naposomes, based on monomers with an upsilon shape (MonY). The upper figure shows the chemical 
structure of the MonY(Gd) monomer. Middle: (A) representation and the structural characterization (relaxation time distributions at 
q = 90° and scattering cross-section at 25°C) of self-assembled aggregates based on MonY(Gd) (left side); (B) representation and the 
structural characterization (relaxation time distributions at q = 90°, scattering cross-sections, and selected cryo-TEM images)  
of mixed aggregates of DOPC/MonY(Gd) at several molar ratios (right). Bottom: (C) NMR dispersion profiles of MonY(Gd) (■) 
and DOPC-MonY(Gd) (80:20) (□) at pH 7.4 and 25°C, normalized to 1 mM concentration of Gd(III) ion (left); (D) binding of 
111In-labeled nanoparticles to A431 cells overexpressing CCK2-R, compared with control cells (right). DLS: Dynamic light scattering; 
DOPC: Dioleoylphosphatidylcholine; SANS: Small-angle neutron scattering; TEM: Transmission electron microscopy.
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naposomes labeled with the 111In indicate tar-
get selectivity both for micelles obtained by 
self-assembling MonY and for mixed liposomes 
containing 20% of MonY in DOPC.
	n Fourth-class naposomes
Fourth-class naposomes are based on ‘gemini’ 
surfactants. In general, gemini surfactants are 
formed by the covalent linking of two ‘conven-
tional’ surfactants via a spacer. These surfactants 
have interesting features, such as low cmc values, 
which drastically reduce cytolytic action on the 
cell membrane [105,106]. By manipulating the 
molecular architecture and the solution condi-
tions, a variety of supramolecular aggregates, 
such as micelles and liposomes, can be obtained. 
According to the naposomes strategy, two gemini 
surfactants have been developed [73]: the first one 
containing the bioactive sequence of the chol-
ecystokinin peptide CCK8[C18CysL
5
CCK8]
2
 
and the second one containing the chelat-
ing agent DTPAGlu or its Gd complex, 
DTPAGlu(Gd), [C18CysDTPAGlu(Gd)]
2
 
(Figure 8). Gemini surfactants were easily syn-
thesized in the solid phase by introducing a 
cysteine residue in the peptide sequence. The 
presence of the cysteine residue in the sequence 
allows disulphur-bridge formation under mild 
oxidative conditions, reducing the purification 
steps. The supra molecular aggregates obtained 
by co-assembling of the two synthetic gemini 
surfactants, at a 70:30 molar ratio between 
chelating agent-containing gemini surfactant, 
or its corresponding Gd(III) complex, and pep-
tide gemini surfactant, have been structurally 
identified as cylindrical or ellipsoidal micelles 
(Figure 8, curly brackets). These mixed aggre-
gates represent the first example of peptide- 
containing gemini surfactants as potential tar-
get-selective contrast agents in MRI. The cmc 
values indicate that all monomers in aqueous 
solution aggregate at the molar concentration 
in the 5·10–6–1·10–5 mol/Kg-1 range. These val-
ues are only slightly lower than cmc values for 
the first class of naposomes (5·10–5 mol/Kg-1) 
and slightly higher than those found for second 
class amphiphiles (5·10–7 mol/Kg-1). Hence, 
gemini compounds present two different effects: 
the higher tendency to aggregate with respect 
to the mono-tailed monomers, and the higher 
electrostatic repulsion between the two head 
groups due to the negative charges of DTPAGlu 
moieties. On the contrary, the cmc value 
(~6·10–6 mol/Kg-1) found for [C18CysL
5
CCK8]
2 
monomer, in which there are no repulsion 
effects, is in agreement with the low expected 
values for gemini surfactants. In fact, the corre-
sponding m ono-tailed monomer (C18L
5
CCK8) 
did not show any t endency to aggregate in the 
same experimental conditions. Moreover, fluo-
rescence spectroscopy confirmed the presence of 
the bioactive peptide well exposed on the aggre-
gate external surface: fluorescence emission at 
approximately 360 nm of the tryptophan indole 
moiety is indicative of the presence of trypto-
phan residue in a polar aqueous solvent, suggest-
ing the presence of the entire CCK8 p eptide on 
the micellar external environment. 
As expected for short peptide sequences the 
CCK8 octapeptide moiety does not undergo any 
folding process in a water solution. On the other 
hand, in micelle aggregates obtained by self-
assembling of (C18)
2
L
5
CCK8, the peptide shows 
a classical b-sheet fold. This result suggests that 
the hydrogen bonds among amino acids, well 
exposed on the external surface of the aggre-
gates, promote intermolecular sheet-like struc-
tures that are stabilized by interactions between 
the alkyl chains. In the present case, according 
to the previous results, the circular dichroism 
spectrum of [C18CysL
5
CCK8]
2
 reveals the 
characteristic shape of a b-sheet-type struc-
ture. Upon heating the solution, the intensity 
of the circular dichroism spectra of the b-sheet 
structure signals (222 nm), decreases linearly, 
suggesting the breaking up of the interactions 
between nearer peptides. By plotting the inten-
sity of the circular dichroism spectra at 222 nm 
as a function of temperature, a sigmoid curve 
is observed. The maximum in the first deriva-
tive of the sigmoid curve indicates the transition 
temperature (T
t
 ~45°C) in which the peptide 
structure changes from a b-sheet to a random 
coil structure. The same result is observed for 
mixed aggregates in which DTPAGlu is present 
as free base or as Gd complex, indicating that, 
CCK8 molecules notwithstanding, their dilu-
tion in (C18CysDTPAGlu)
2
 aggregates, are still 
close enough to each other to maintain hydrogen 
bonds among peptide chains (Figure 8a). The 
shape and size of pure and mixed aggregates 
are also influenced by the temperature: at lower 
temperatures micelle aggregates have elongated 
shapes with a cylindrical structure, while at 
higher temperatures ellipsoidal shapes are found 
(Figure 8b). It seems that the increase of the tem-
perature leads to progressive shortening of the 
cylindrical structures up to ellipsoidal micelles. 
Likewise, the surface-exposed CCK8 peptide 
changes its conformation by increasing the 
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Figure 8. Fourth-class naposomes, based on Gemini surfactants. The upper part of the figure shows a representation of 
[C18CysDTPAGlu(Gd)]
2
 and [C18CysL
5
CCK8]
2
 gemini amphiphilic monomers, obtained by connecting two identical moieties by a 
disulphide bond. In the curly brackets is a schematic representation of the [C18CysDTPAGlu(Gd)]
2
/[C18CysL
5
CCK8]
2
 aggregates (70:30 
molar ratio); their shape is temperature dependent. In the bottom side of the panel is reported the structural characterization and 
relaxometric behavior of the [C18CysDTPAGlu(Gd)]
2
–[C18CysL
5
CCK8]
2
 system (pH 7.4, 1∙10–4M concentration of the gemini peptide is 
reported): (A) circular dichroism spectra of aggregate solution recorded in the 10–80°C range; (B) Scattering cross-sections measured 
heating up aggregates at the temperatures reported in the legend. Cross-sections have been multiplied for a scale factor, as indicated; 
(C) NMR dispersion profiles recovered at 25°C, normalized to 1 mM concentration of Gd(III) ion.
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temperature, going from a b-sheet to a random 
coil structure. Even if there is any evidence that 
the two phenomena are related, the similarity of 
the transition temperatures of the two processes, 
as well as the amplitude of the hysteresis indicate 
a possible co-operation between the aggregate 
structure transition and the peptide conforma-
tion variation. In Figure 8C the relaxivity values 
of pure and mixed micelles at 25°C (18.4 and 
21.5 mM-1s-1, respectively) are reported. These 
values are in accordance with the other classes 
of naposomes and with other Gd-containing 
micelle systems, as almost all the q = 1 (one 
inner-sphere water molecule) Gd-based micelles 
have relaxivity values in the range 18–23 mM-1s-1 
(20 MHz; 25°C) for each Gd atom. 
Future perspective
Biological tests of naposomes show proper-
ties that appear potentially suitable for clinical 
applications: significantly higher concentration 
of aggregates in receptor-expressing xenografts 
relative to controls has been established in vivo, 
suggesting that these aggregates may be utilized 
to increase concentration of the Gd MRI con-
trast agent and/or of a drug, to cells expressing 
a specific receptor target.
Slow plasma kinetics with prolonged half-
life and low breakdown of the supramolecular 
aggregates, both probably due to the presence 
of PEG moieties on the aggregate external sur-
face, appear useful for maintaining high blood 
concentrations of the delivered compound.
The long circulation times, the elevated spe-
cific targeting properties of the aggregates and 
their selective cytotoxic efficiency on the target 
cells, are in line with the desired pharmaco-
kinetic properties of a drug-delivery nanovector. 
These results indicate that naposomes, in 
which CCK8, 7-14-BN, or octreotide peptides are 
exposed on the external aggregate surface, could 
efficiently act as target-selective tools for delivery 
of a contrast agent (paramagnetic Gd complexes 
for MRI, or radioactive metal ions for MRI or 
scintigraphic images, respectively) and/or drugs 
to cancer cells overexpressing specific membrane 
receptors. By combining the contrast agent and 
the drug in the same nanoparticle, naposomes 
r epresent efficiently theradiagnostic systems. 
The development of naposome lead compounds 
containing the BN peptide on their external sur-
face for imaging and therapeutic application in 
ovarian cancer is in progress. The first Phase 1 
clinical studies are scheduled for coming years.
Executive summary
	n New supramolecular aggregates – termed naposomes – with shapes and sizes that can be modulated at will, containing chelating 
agents and bioactive peptides and acting as effective and selective delivery tools for drug and/or contrast agents have been developed in 
recent years. They represent a new generation of theradiagnostic nanoparticles.
	n Naposomes are supramolecular aggregates (micelles, vesicles or liposomes) obtained by coaggregation of two monomers: a first 
monomer containing a chelating agent that is able to coordinate a radioactive or paramagnetic metal ion and having a lipophilic moiety, 
and a second monomer containing a bioactive peptide linked to a similar lipophilic moiety.
	n The aggregates are selectively driven by the exposed bioactive peptide on the chosen biological target. Oxo-ethylene moieties 
(polyethylene glycol units) are introduced to space the bioactive peptide from the aggregate external surface and to improve the in vivo 
permanence of the aggregates.
	n The aggregates are able to entrap in their inner compartment or in the phospholipid bilayer, a pharmaceutical active principle, for 
example the cytotoxic drug doxorubicin (DOX). 
	n Four different classes of naposomes, based on the combination of different monomers, are discussed. The bioactive peptides exposed 
on their external surface are: CCK8, 7-14-bombesin and octreotide. 
	n The innovative aspects related to naposomes, with respect to liposomal drugs already in use (Myocet®, liposomial DOX and DOXIL® 
polyethylene glycolhilated liposomal DOX), concerns the presence of the bioactive peptides well exposed on the aggregate external 
surface, which allows selective delivery to cancer cells overexpressing membrane receptors for the bioactive peptide. Moreover, the 
presence of the chelating agent allows the aggregates to achieve several goals according to the complexed metal ion.
	n Effective and selective drug-delivery systems containing a marker that is able to monitor the in vivo circulation and the in vivo 
biodistibution of the drug-containing aggregate can be achieved by using nuclear medicine techniques if the metal is represented by a 
g-emitting (111In, 99mTc[V] or 67Ga[III]) isotope. 
	n Naposomes have a high relaxivity and are target-selective contrast agents for MRI application. 
	n Naposomes are an effective and selective drug-delivery system, and a powerful radiotherapeutic compound containing, simultaneously, 
a drug entrapped in the inner compartment of the aggregate and a b-emitting radioactive metal ion (90Y[III] or 177Lu[III]) complexed by 
the chelating agent.
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